Search | Clinical Trials Finder

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Palm Springs, California + 15 more

Conditions: Attention - no Condition is Being Assessed - Healthy Adults
Interventions: Modafinil; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 52
States / cities: Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more

Conditions: Chronic Lymphocytic Leukemia, CLL
Interventions: Oblimerson sodium, G3139; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 3
States / cities: New Hyde Park, New York • Houston, Texas • San Antonio, Texas

Conditions: Metabolic Syndrome
Interventions: Higher protein, low glycemic load diet; Dietary Supplement
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Systemic Lupus Erythematosus
Interventions: GLPG3667, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: Venetoclax, Azacitidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 58
States / cities: Fullerton, California • Los Angeles, California • Torrance, California + 50 more

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 16 more

Conditions: Central Nervous System Tumor
Interventions: tozuleristide, Canvas imaging system, Surgical resection of tumor; Drug · Device · Procedure
Lead sponsor: John Yu; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: fenretinide; Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Pemetrexed; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Brain Tumor, Pediatric
Interventions: Brief Internet-based Behavioral Activation Intervention; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriatic Arthritis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more

Conditions: Rheumatoid Arthritis
Interventions: Milnacipran; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions: Seribantumab; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more

Conditions: Type 1 Diabetes
Interventions: iHERO Toolkit Resource; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Cleveland, Ohio + 1 more

Conditions: Gout, Hyperuricemia
Interventions: Subsidy for food purchases and dietitian education; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Woodlawn, Maryland • Boston, Massachusetts

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions: doxorubicin hydrochloride; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma
Interventions: Miltenyi CliniMACS Prodigy ® system, Zoledronic acid; Device · Drug
Lead sponsor: University of Florida; Other
Eligibility: 6 Months to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Severe Hypertriglyceridemia
Interventions: Solbinsiran, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more

Conditions: Colorectal Cancer
Interventions: adenoma vs no adenoma, colonoscopy vs no colonoscopy, survey and expert panel; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 75 Years and older
Enrollment: 130,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Diego, California • West Los Angeles, California

Conditions: Brain and Central Nervous System Tumors
Interventions: temsirolimus; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 7 more

Conditions: Acne, Patient Compliance
Interventions: Text message reminders; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Dallas, Texas

Search by objective public record fields.

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Investigation of Locus Coeruleus Function in Sustained Attention

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Diet and Health in Adults With Metabolic Syndrome

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Promotion of Well-being of Young Adult Brain Cancer Survivors

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

The Diet Gout Trial

Impact of Liraglutide 3.0 on Body Fat Distribution

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

CCI-779 in Treating Patients With Malignant Glioma

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"